Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 28;21(1):1111.
doi: 10.1186/s12879-021-06780-7.

COVID-19 underreporting and its impact on vaccination strategies

Affiliations

COVID-19 underreporting and its impact on vaccination strategies

Vinicius Albani et al. BMC Infect Dis. .

Abstract

Background: Underreporting cases of infectious diseases poses a major challenge in the analysis of their epidemiological characteristics and dynamical aspects. Without accurate numerical estimates it is difficult to precisely quantify the proportions of severe and critical cases, as well as the mortality rate. Such estimates can be provided for instance by testing the presence of the virus. However, during an ongoing epidemic, such tests' implementation is a daunting task. This work addresses this issue by presenting a methodology to estimate underreported infections based on approximations of the stable rates of hospitalization and death.

Methods: We present a novel methodology for the stable rate estimation of hospitalization and death related to the Corona Virus Disease 2019 (COVID-19) using publicly available reports from various distinct communities. These rates are then used to estimate underreported infections on the corresponding areas by making use of reported daily hospitalizations and deaths. The impact of underreporting infections on vaccination strategies is estimated under different disease-transmission scenarios using a Susceptible-Exposed-Infective-Removed-like (SEIR) epidemiological model.

Results: For the considered locations, during the period of study, the estimations suggest that the number of infected individuals could reach 30% of the population of these places, representing, in some cases, more than six times the observed numbers. These results are in close agreement with estimates from independent seroprevalence studies, thus providing a strong validation of the proposed methodology. Moreover, the presence of large numbers of underreported infections can reduce the perceived impact of vaccination strategies in reducing rates of mortality and hospitalization.

Conclusions: pBy using the proposed methodology and employing a judiciously chosen data analysis implementation, we estimate COVID-19 underreporting from publicly available data. This leads to a powerful way of quantifying underreporting impact on the efficacy of vaccination strategies. As a byproduct, we evaluate the impact of underreporting in the designing of vaccination strategies.

Keywords: Epidemiological models; Numerical simulation; Stable rates of hospitalization and death; Underreported infections; Underreporting estimation; Vaccination strategies.

PubMed Disclaimer

Conflict of interest statement

All authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Methodological workflow for the underreporting quantification
Fig. 2
Fig. 2
Left: Daily numbers of performed and positive tests of COVID-19 in Chicago. Right: The corresponding daily positive rate. The period is 01-Mar-2020 to 23-Dec-2020. The solid horizontal line represents a reference of 10%
Fig. 3
Fig. 3
Daily rates of hospitalization (left), death (center) and death amongst hospitalized individuals (right) from 01-Mar-2020 to 23-Dec-2020, in Chicago. The dark area shows the period when the rate seems to stabilize, i.e., 01-Aug2020 to 05-Oct-2020. The horizontal solid lines represent the median of the rates observed during 01-Aug-2020 to 05-Oct-2020
Fig. 4
Fig. 4
Daily rates of hospitalization (left), death (center) and death amongst hospitalized individuals (right) from 01-Mar-2020 to 23-Dec-2020, in Chicago, for each age range. The dark area shows the period when the rate seems to stabilize, i.e., 01-Aug-2020 to 05-Oct-2020. The horizontal solid lines represent the median values of the rates observed during 01-Aug-2020 to 05-Oct-2020
Fig. 5
Fig. 5
Schematic representation of the SEIR-type model in Eqs. (345678910)–(11)
Fig. 6
Fig. 6
Corrected and reported series of daily infections in Chicago from 01-Mar-2020 to 23-Dec-2020, using the rates of hospitalization (left column) and death (right column) from Table 1. First row uses the daily reports, the second uses daily reports by gender, and the third one uses daily reports by age range. The filled envelopes are 90% confidence intervals (CIs)

References

    1. Gibbons C, Mangen M-J, Plass D, Havelaar A, Brooke R, Kramarz P, Peterson K, Stuurman A, Cassini A, Fèvre E, et al. Measuring underreporting and under-ascertainment in infectious disease datasets: a comparison of methods. BMC Public Health. 2014;14(1):1–17. doi: 10.1186/1471-2458-14-147. - DOI - PMC - PubMed
    1. Demonbreun AR, McDade TW, Pesce L, Vaught LA, Reiser NL, Bogdanovic E, Velez MP, Hsieh RR, Simons LM, Saber R, Ryan DT, Ison MG, Hultquist JF, D’Aquila Wilkins RT JT, Mustanski B, McNally EM. Patterns and persistence of SARS-CoV-2 IgG antibodies in Chicago to monitor COVID-19 exposure. JCI Insight. 2021 doi: 10.1172/jci.insight.146148. - DOI - PMC - PubMed
    1. Stadlbauer D, Tan J, Jiang K, Hernandez MM, Fabre S, Amanat F, Teo C, Arunkumar GA, McMahon M, Capuano C, Twyman K, Jhang J, Nowak MD, Simon V, Sordillo EM, van Bakel H, Krammer F. Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City. Nature. 2021;590(7844):146–150. doi: 10.1038/s41586-020-2912-6. - DOI - PubMed
    1. Espenhain L, Tribler S, Sværke Jørgensen C, Holm Hansen C, Wolff Sönksen U, Ethelberg S. Prevalence of SARS-CoV-2 antibodies in Denmark 2020: results from nationwide, population-based sero-epidemiological surveys. medRxiv preprint. 2021 doi: 10.1101/2021.04.07.21254703. - DOI - PMC - PubMed
    1. Muñoz-Medina JE, Grajales-Muñiz C, Salas-Lais AG, Fernandes-Matano L, López-Macías C, Monroy-Muñoz IE, Santos Coy-Arechavaleta A, Palomec-Nava ID, Duque-Molina C, Madera-Sandoval RL, et al. Sars-cov-2 igg antibodies seroprevalence and sera neutralizing activity in Mexico: a national cross-sectional study during 2020. Microorganisms. 2021;9(4):850. doi: 10.3390/microorganisms9040850. - DOI - PMC - PubMed